Plasminogen相关论文
...
[Objective]The influence of Hirulog-s in mutual activation reaction system constituted by single chain urokinase-type pl......
很少有研究对接受急性卒中治疗的80岁以上患者的临床转归进行探讨。美国哥伦比亚大学的Willey等进行了一项研究，对≥80岁的患者与年......
尽管存在早期有症状颅内出血（symptomatic intracranial hemorrhage，slCH）风险，但静脉重组组织型纤溶酶原激活剂（recombinant tissue-ty......
根据第23届欧洲卒中大会（European Stroke Conference，ESC）报道的一项回顾性研究结果，大脑中动脉（middle cerebral artery，MCA）M1段闭塞长......
在以往的研究中，血管事件患者总体健康风险（Totaled Health Risksin Vascular Events，THRIVE）评分已经显示出广泛的用途，使预测临床转归......
期刊
静脉组织型纤溶酶原激活剂（tisue plasminogen activator，tPA）治疗急性缺血性卒中（acute ischemicstroke，AIS）的获益呈时间依赖性，指南建......
0．9mg/kg组织型纤溶酶原激活物（tissue plasminogen activator，tPA）静脉溶栓治疗可改善急性缺血性卒中患者的转归。与西方人相比，中国人......
重组组织型纤溶酶原激活物（recombinant tissue plasminogen activator，rtPA）溶栓治疗是目前3h时问窗（最近扩大到4．5h）可实施的唯一批准......
2004年7月至2007年6月，德国海德堡大学的F6rster等在发病3h内接受重组组织型纤溶酶原激活物（recombinant tissue plasminogen activa......
美国密歇根州立大学的Archit等进行的一项汇总分析表明，急性缺血性卒中（acute ischemic stroke，AIS）发病后，女性接受组织型纤溶酶原激活......
女性的卒中自然史比男性更差。有关不同性别缺血性卒中患者接受重组组织型纤溶酶原激活物（recombinant tissue plasminogen activat......
替奈普酶（tenecteplase，TNK）是组织型纤溶酶原激活剂（tissue plasminogen activator，tPA）的一种改良形式，其半衰期更长，与纤维蛋白的亲和力......
静脉组织型纤溶酶原激活剂（tissue plasminogen activator，tPA）是目前公认的急性卒中标准治疗。1996年，美国食品药品管理局在美国国立......
组织型纤溶酶原激活剂（tissue plasminogen activator，tPA）是美国食品药品管理局批准用于缺血性卒中紧急治疗的唯一一种溶栓药，但仅限......
业已证实，2MHz经颅多普勒（transcranial Doppler，TCD）持续监测可增强急性颅内动脉闭塞患者的静脉溶栓效果。据推测，其机制可能是由于超......
机体的正常止血功能由血凝与纤维蛋白溶解之间的平衡得以维持,止血平衡紊乱与某些肾脏疾病的发病机理密切相关。本文详述溶血性尿......
Hypercoagulability observed in patients with inflammatory bowel diseases(IBD)may lead to thromboembolic events(TE),which......
Three tissue-type plasminogen activator(t-PA)mutants were constructed by recombinant andsite-directed mutagenesis techni......
PAI-1 is the primary physiologic inhibitor of urokinase-type plasminogen activator (uPA) and tissue-type plasminogen act......
Objective:To explore the relationship between polymorphism of PAI-1 gene and type 2 diabetes mellitus(DM} , hyperten-si......
Elevation of serum urokinase plasminogen activator receptor and liver stiffness in postoperative bil
AIM To investigate serum urokinase-type plasminogen activator receptor(u PAR) and liver stiffness in biliary atresia(BA)......
Objective To investigate the role of plasminogen activator inhibitor-1(PAI-1)in the inhibition of rosiglitazone on the t......
糖尿病(diabetes mellitus)特别是2型糖尿病(T2DM)存在凝血纤溶系统的变化.。表现为凝血活性增强.、纤溶活性减低及抗凝物质减少,......
目的探讨尿激酶型纤溶酶原激活物(urokinase plasminogen activator,uPA)在子宫内膜异位症发病机制中的作用。方法应用免疫组织化......
AIM:To investigate the role of tissue plasminogen activator(t-PA) and plasminogen activator inhibitor(PAI)in proliferati......
Tissue—type plasminogen activator(t—PA)plays an important role in fibrinolytic system.A spec-trophotometric solid—ph......
Objective:This study aims to determine the mechanisms underlying restenosis and ischemia-reperfusion injury of the myoca......
纤溶酶原激活物抑制剂1(plasminogen activator inhibitor-1,PAI-1)4G/5G多态性与高血压有关。近年来已证实,中心动脉压比肱动脉压......
To investigate the expression and clinical significance of urokinase type plasminogen activator (uPA) in human gliomas ......
AIM:To evaluate the relationship between uPA,PAI-1,CEA,PI3K and metastatic potential in three colorectal tumorcell line......
纤溶酶原的激活在肿瘤的侵袭、转移中发挥着重要作用,其基本理论是从肿瘤细胞分泌的纤溶酶原激活物催化水解无活性的纤溶酶原转变......
Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth f
AIM:To investigate the relationship of urokinase type plasminogenactivator receptor (uPAR) and vascular endothelial gro......
Simvastatin is a hypolipidemic drug that inhibits hydroxymethylglutaryl coenzyme A (HMGCoA) reductase to control elevate......
新生血管对于肿瘤的的生长、浸润和转移具有重要的意义，当瘤体体积超过1-2mm^3时就需要新生血管提供营养维持代谢，同时提供转移通路......
Angiostatin is a 38 ku circulating angiogenesis inhibitor purified from the serum and urine of mice bearing a murine Lew......
美国华盛顿消息:欧洲的几项试验表明,急性心肌梗塞时静脉推注速效血栓溶解剂(APSAC)可与链激酶输注相匹敌。美国多中心试验的初步......
对于不适合行静脉组织型纤溶酶原激活物（tissue plasminogen activator，tPA）的急性缺血性卒中患者，动脉内溶栓治疗可作为一种替代治疗......
组织纤维蛋白溶酶原活化剂(tissueplasminogen activator,简称t-PA),组织纤溶酶原活化剂是一种有前途的新型溶栓药物。由于t-PA对......
Experimental study on mRNA and protein expression of urokinase type plasminogen activator in human b
Objective: To investigate the relationship between urokinase type plasminogen activator(uPA) activityand the malignant b......
目的 初步探讨人类纤溶酶原激活物抑制物 - 1(plasminogen ativator inhibitor- 1,PAI- 1)启动子区基因多态性与脑血管病的关系 ,......
ＲｅｌａｔｉｏｎｓｈｉｐｂｅｔｗｅｅｎｌｅｖｅｌｓｏｆｐｌａｓｍｉｎｏｇｅｎａｃｔｉｖａｔｏｒｓａｎｄｇａｓｔｒｉｃｃａｎｃｅｒＸＵＧｕｏＱｉｎｇ，ＨＵＡＮＧＨｕａｉＤｅ，ＺＨＵＺｈｉＪｉａｎ，ＰＥＮＧＱｉｎｇＢｉａｎｄＷＡＮＧＫａｉＭ...
RelationshipbetweenlevelsofplasminogenactivatorsandgastriccancerXUGuoQing, HUANGHuaiDe, ZHUZh......
The relativity of the activity change of tissue-type plasminogen activator and type 1 plasminogen ac
AIM:To explore the dynamic changes of the activity of tissue type plasminogen activator (t PA) and type 1 plasminogen ......
期刊
INTRODUCTIONPlasminogen activator inhibitor type 1(PAI-1),anapproximately Mr 50000 glycoprotein,is the majorphysiologic......
Interventional effect of flunarizine on the expression of cyclooxygenase-2 and plasminogen activator
BACKGROUND: Some researches suggest that induced cyclooxygenase-2 (COX-2) can cause brain injury through a series of way......
业已证实，颈内动脉／大脑中动脉串联（tandem internal carotid artery/middle cerebral artery，TIM）闭塞与静脉组织型纤溶酶原激活剂（tiss......
Expression of matrix metalloproteinases and tissue inhibitor metalloproteinases increases in X-irrad
AIM: To investigate their expression and activity in the rat ileum after exposure to ionizing radiation along with that ......
Association of plasminogen activator inhibitor-1 4G/5G promoter polymorphism with recurrent cerebral
BACKGROUND: Many international studies have shown that plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorp......
目的探讨CT灌注成像渗透性表面积(permeabili-ty-surface area product,PS)图在急性缺血性脑卒中病人出血性转化中的作用。方法此......
The neuroprotective effect of Zhutan Tongluo Tang is associated with the activities of the fibrinolytic system. Thus the......
